Home » FDA Says All Off-Label Communications Can Fall Within Regulatory Purview

FDA Says All Off-Label Communications Can Fall Within Regulatory Purview

February 8, 2017

Pharmaceuticals Regulatory Affairs

The First Amendment does not preclude drugmakers from FDA’s oversight of off-label communication even if what they say is truthful.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $40.00

21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements